Furthermore, higher levels of SAM could promote methylation as evidenced by elevated levels of methylated metabolites like N-methylglycine, a.k.a. sarcosine, 2-methyl glutaric acid, dimethylglycine, methyl alanine etc in prostate cancer cells upon androgen treatment, as well as increased expression of methyltransferases like EZH2, in metastatic disease. Here, EZH2 is linked to prostate carcinoma.